Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas
Abstract:Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas.
Acta Neurol Scand 2007: 116: 380–384.
© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard. Objectives –
To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas. Materials and methods –
GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas. A database with clinical, radiological and histological variables was created for statistical analyses. Results –
Mean serum levels of 239 ng/l (range 30–1210 ng/l) for GFAP and 58.3 ng/l (range 22–128 ng/l) for S-100B were found. Of the 31 patients, 16 had elevated levels of GFAP while only two showed increased S-100B concentrations. Tumour size was the only variable significantly associated with serum levels of GFAP (P < 0.0001) with a linear correlation coefficient of 0.67. Conclusions –
Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas. GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.
Document Type: Research Article
Affiliations: 1: Neurosurgical Department, University Hospital of North Norway, Tromsø, Norway 2: Institute of Clinical Neuroscience, Department of Neurology, Gothenburg University, Sahlgrenska University Hospital, Gothenburg, Sweden 3: University of Tromsø, Tromsø, Norway 4: Department of Pathology, University Hospital of North Norway, Tromsø, Norway
Publication date: 2007-12-01